News

Filter

Current filters:

AbraxaneRoche

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Advent of generics will keep breast cancer drug market static over the next decade

12-04-2011

The breast cancer drug market will remain largely static over the next decade, increasing from $10.2…

AbraxaneAvastinCelgeneEli LillyGenericsGlobalMarkets & MarketingOncologyPharmaceuticalramucirumabRoche

APP reports start of Ph II trial of Abraxane/Herceptin

18-04-2005

American Pharmaceutical Partners has announced the start of enrollment in a 70-patient Phase II study…

AbraxaneAlbuminAlbumin-bound PaclitaxelAlbuminarBuminate 5%Herceptinintravenous infusionMulti Vitamin ConcentratePaclitaxelRocheTaxoltrastuzumab

Back to top